Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Leases (2019 - 2025)

BridgeBio Pharma's Current Leases history spans 7 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Current Leases rose 37.42% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, up 37.42%, while the annual FY2025 figure was $6.2 million, 37.42% up from the prior year.
  • Current Leases for Q4 2025 was $6.2 million at BridgeBio Pharma, up from $5.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $6.2 million in Q4 2025 and bottomed at $3.7 million in Q1 2023.
  • The 5-year median for Current Leases is $4.5 million (2021), against an average of $4.5 million.
  • The largest annual shift saw Current Leases decreased 25.58% in 2022 before it soared 37.42% in 2025.
  • A 5-year view of Current Leases shows it stood at $4.9 million in 2021, then fell by 25.58% to $3.7 million in 2022, then grew by 12.33% to $4.1 million in 2023, then grew by 9.16% to $4.5 million in 2024, then surged by 37.42% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Current Leases are $6.2 million (Q4 2025), $5.3 million (Q3 2025), and $4.8 million (Q2 2025).